ArticleJournal of gastrointestinal oncology2022

Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.

Jian Zhai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.